



Andrew Bonnes

PARTNER

BOSTON

+ 1 617 526 6136

ANDREW.BONNES@WILMERHALE.COM

As a leading corporate lawyer and trusted business advisor, Andrew focuses his practice on mergers and acquisitions and public company counseling. He has represented buyers, sellers, boards of directors, significant investors, financial advisors and other interested parties in mergers, acquisitions, divestitures, investments, joint ventures, alliances, PIPEs and other strategic transactions across a broad range of industries. He has also advised public companies on a variety of corporate matters, including corporate governance, fiduciary duties, securities law compliance and defensive measures. Learn more about Mr. Bonnes' practice and how he can support your startup on WilmerHaleLaunch.com.

Community Involvement

Andrew maintains an active pro bono practice, representing organizations such as Digital Public Library of America and Epilepsy Foundation New England on a variety of matters.

Solutions

Capital Markets

Cross-Border Transactions

Emerging Company and
Venture Capital

Life Sciences

Mergers and Acquisitions

Private Equity

SPAC (Special Purpose
Acquisition Company)
Transactions

Technology

Experience

Over the course of his career, Mr. Bonnes has represented clients on a variety of significant transactions. Some of his experience includes representing:

- Acacia Communications in its acquisition by Cisco Systems for \$4.5 billion in cash and assumed equity awards
- Alcon in the merger resulting in sale of its outstanding public shares to Novartis for approximately \$12.9 billion
- American Science and Engineering in its acquisition by OSI Systems for \$269 million
- Analogic Corporation in its acquisition by an affiliate of Altaris Capital Partners for \$1.1 billion
- Arch Chemicals in its sale to the Lonza Group for approximately \$1.4 billion
- Casella Waste Systems in its acquisition of the assets of Youngblood Disposal Enterprises of Western New York
- Cynosure in its acquisition by Hologic for \$1.65 billion
- Editas Medicine in its acquisition of i2 Pharmaceuticals' assets and capabilities for guide RNA engineering and manufacturing
- Endurance International Group in multiple transactions including:
 - its acquisition by Clearlake Capital Group for \$3 billion
 - its acquisition of Retention Science
 - the sale of its SinglePlatform digital storefront business to TripAdvisor
 - the purchase of its largest co-located data center from ACE Data Centers and Ace Holdings
 - its acquisition of the Verio hosting business of NTT America
 - its acquisition of the BuyDomains business of NameMedia
 - its acquisition of Typepad LLC
 - its acquisition of the Directi web presence business from Directi Web Technologies Holdings
- Entegris, Inc. in its acquisition of Digital Specialty Chemicals Limited
- EverQuote in multiple transactions including:
 - its acquisition of Crosspointe Insurance & Financial Services
 - its acquisition of PolicyFuel
- General Catalyst in multiple transactions including:
 - the \$18.5 billion merger of its portfolio company Livongo with Teladoc Health
 - the \$1.125 billion sale of its portfolio company Clarabridge
 - the sale of its portfolio company ClassPass to Mindbody in a stock-for-stock merger, as well as a strategic investment of \$500 million in the combined company in conjunction with the acquisition
 - the sale of its portfolio company Digit to Oportun Financial for approximately \$212.9 million

- the sale of its portfolio company 6D.ai to Niantic
- the growth investment in its portfolio company Photoshelter by Clearhaven Partners
- the sale of its portfolio company Stellar Aurora (creator of the messaging platform Quill) to Twitter
- the growth investment in its portfolio company Yottaa by PSG
- Genpact Limited in connection with a \$1 billion equity investment by Bain Capital
- Health Monitor Network in a significant growth capital investment by private equity firm WestView Capital Partners
- Hydra Biosciences in the sale of its pre-clinical pain program to Eli Lilly and Company
- IBM in the sale of its global retail store solutions business to Toshiba Tec for approximately \$850 million
- Jebbit in its \$70 million strategic growth investment by Vista Equity Partners
- Kadant in its acquisition of Syntron Material Handling Group
- Karyopharm Therapeutics in the sale of its investigational oral SINE compound KPT-350 and other assets for the treatment of certain neurological and neurodegenerative condition to Biogen
- The Board of Directors of Par Pharmaceutical Companies in its sale to TPG Capital for \$1.9 billion
- PerkinElmer in its acquisition of BioLegend for \$5.25 billion
- Progress in multiple transactions including:
 - its acquisition of Kemp for \$258 million
 - its acquisition of Chef for \$220 million
 - its acquisition of Ipswitch for \$225 million
- QD Vision in the sale of quantum dot related intellectual property to Samsung
- Regal Entertainment Group in its acquisition by Cineworld Group for \$5.9 billion, including the assumption of debt and net of cash acquired
- Stackdriver in its acquisition by Google
- Staples in its attempted acquisition of Office Depot for \$6.3 billion (terminated) and its acquisition by Sycamore Partners for \$6.9 billion
- Starbucks in its acquisition of Teavana for approximately \$620 million
- Sonus Networks in multiple transactions including:
 - its acquisition of Taqua
 - its acquisition of the SDN technology assets of Treq Labs
- Takeda Pharmaceutical Company, through its wholly-owned subsidiary Millennium Pharmaceuticals, in a five-year collaboration with Maverick Therapeutics
- Thermo Fisher Scientific in its acquisition of Gatan, a wholly owned subsidiary of Roper, for approximately \$925 million

- Vail Resorts in its acquisition of Peak Resorts, the owner of 17 ski resorts in the Northeastern, Mid-Atlantic and Midwestern United States, for \$264 million
- Veveo in its acquisition by Rovi Corporation
- Viamet Pharmaceuticals in its sale to NovaQuest Capital Management
- WEX in several transactions including:
 - its acquisition of benefitexpress for \$275 million
 - its acquisition of Discovery Benefits for \$425 million
 - its acquisition of Noventis for \$310 million
 - the acquisition of certain health savings account assets from the HealthcareBank division of Bell Bank for \$250 million and up to \$225 million in contingent consideration
 - a \$400 million dollar PIPE investment from an affiliate of Warburg Pincus
 - its acquisition of Electronic Funds Source for \$1.1 billion in cash and 4.0 million shares of its common stock
 - its acquisition of eNett International (Jersey) Limited and Optal Limited for \$578 million

Recognition

- Named to *Boston Magazine's* inaugural Top Lawyers list in 2021, 2022 and 2023 in the area of corporate law.
- Recommended in the 2019 edition and named a “Next Generation Lawyer” in the 2022 edition of *The Legal 500 United States* for his work in M&A: Middle-Market.

Credentials

EDUCATION

JD, University of Pennsylvania
Law School, 2007

cum laude

*Executive Editor, University of
Pennsylvania Law Review,
Order of the Coif*

BA, Dartmouth College, 1998

ADMISSIONS

Massachusetts

New York